Andrew J. Schwab

CIK 1598549 · Co-CEO · last filed 2026-08-31

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$129.45M

Companies

16

Total Filings

44

Lifetime Open-Market Net

-$183.43M

Filer Profile

Reported Address
C/O 5AM VENTURE MANAGEMENT, LLC
4 EMBARCADERO CENTER, SUITE 3110
SAN FRANCISCO, CA 94111
Related Filers
SCOTT M ROCKLAGE — 71 joint filings, latest 2026-08-10
5AM Opportunities I (GP), LLC — 49 joint filings, latest 2026-08-10
5AM Opportunities I, L.P. — 49 joint filings, latest 2026-08-10
JOHN D DIEKMAN — 49 joint filings, latest 2023-04-12
5AM Co-Investors IV, L.P. — 34 joint filings, latest 2023-04-12
5AM Partners IV, LLC — 34 joint filings, latest 2023-04-12
5AM Ventures IV, L.P. — 34 joint filings, latest 2023-04-12
5AM Partners V, LLC — 27 joint filings, latest 2026-08-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CAMP Director 2,033,270 $4.25 $8.64M $7.50M 8 2026-08-31
SKYE Director 6,901 $2.04 $14.1K -$2.69M 7 2026-08-20
TRDA 10%+ Owner 3,941,623 $6.80 $26.80M -$4.84M 1 2026-08-03
ARTV 10%+ Owner 1,182,054 $10.22 $12.08M $60.00M 1 2024-07-24
Enliven Therapeutics, Inc. (IMRA) Delisted Director 3,888,992 $14.59 $56.74M -$45.00M 3 2024-02-02
Pear Therapeutics, Inc. (PEARW) Delisted Director 12,989,936 $0.01 $76.6K -$8.38M 2 2022-09-16
RLYB 10%+ Owner 162,760 $16.88 $2.75M -$7.80M 1 2022-05-25
IPI Legacy Liquidation Co (IMPL) Delisted 10%+ Owner 1,849,456 $0.24 $445.9K $60.38M 1 2021-04-29
CABA 10%+ Owner 380,218 $2.73 $1.04M -$35.22M 1 2021-01-12
5:01 Acquisition Corp. (FVAM) Delisted Co-CEO 365,126 $10.00 $3.65M $0 4 2020-12-01
scPharmaceuticals Inc. (SCPH) Delisted 10%+ Owner 3,123,303 $5.67 $17.71M $5.00M 1 2020-05-28
ARVN 10%+ Owner 3,888,216 $8.45 $32.86M -$106.29M 2 2019-07-01
CRNX 94,489 $84.95 $8.03M -$33.30M 1 2019-06-25
FIXX 10%+ Owner 1,367 $13.72 $18.8K -$82.79M 2 2019-05-20
EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted 10%+ Owner 65,699 $10.00M 1 2015-02-06
FLXN Director 1,512,076 $24.62 $37.23M $0 2 2014-03-04

Recent Filings · Page 4 of 5

44 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-01-12 CABA Sell (S) −2,709,000 -$35.22M EDGAR
2020-12-01 5:01 Acquisition Corp. (FVAM) Delisted Other (J) $0 EDGAR
2020-11-18 5:01 Acquisition Corp. (FVAM) Delisted Other (J) $0 EDGAR
2020-11-12 5:01 Acquisition Corp. (FVAM) Delisted Other (J) +5,126 $51.3K EDGAR
2020-10-20 5:01 Acquisition Corp. (FVAM) Delisted Other (J) +360,000 $3.60M EDGAR
2020-05-28 scPharmaceuticals Inc. (SCPH) Delisted Buy (P) +578,034 $5.00M EDGAR
2019-07-01 ARVN Sell (S) −4,860,000 -$106.29M EDGAR
2019-06-25 CRNX Sell (S) −1,500,000 -$33.30M EDGAR
2019-05-20 FIXX Sell (S) −3,690,000 -$79.22M EDGAR
2018-11-27 FIXX Sell (S) −178,092 -$3.57M EDGAR
Showing 3140 of 44
Page 4 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.